Loading clinical trials...
Loading clinical trials...
A Phase I Study to Determine the Maximum Tolerated Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of NM6603 in Patients With Advanced Solid Tumors
Conditions
Interventions
NM6603
Locations
4
United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
Tennessee Oncology, PLLC
Nashville, Tennessee, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
August 31, 2023
Primary Completion Date
October 31, 2025
Completion Date
February 28, 2026
Last Updated
June 12, 2025
NCT07489378
NCT03340506
NCT00242723
NCT07186842
NCT06902623
NCT06810375
Lead Sponsor
NucMito Pharmaceuticals Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions